INEOS warns that European pharmaceutical supply chains and manufacturing capacity are imperiled by high energy costs, carbon taxes, and lack of regulatory support, calling for urgent EU intervention.

The FDA has restricted updated COVID-19 vaccine approvals to seniors and certain high-risk individuals under 65, ending routine access for healthy children and pregnant women and raising operational, regulatory, and supply chain concerns across the pharma sector.

Innovent Biologics and Takeda have announced a sweeping $11.4 billion oncology alliance focused on global co-development and commercialization of immuno-oncology and ADC drug candidates.

Cambrex announces a major $120 million investment to expand active pharmaceutical ingredient (API) manufacturing capacity in the U.S., targeting enhanced supply chain resilience.

EVOQ Therapeutics has entered into a Collaboration and Licence Agreement with Sanofi. The partnership focuses on advancing EVOQ’s proprietary NanoDisc technology, which aims to restore the body’s natural immune tolerance mechanisms. 

Minovia Therapeutics Ltd. a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline

Celltrion has received approval from the U.S. Food and Drug Administration (FDA) for EYDENZELT® (aflibercept-boav), a biosimilar referencing EYLEA® (aflibercept). 

Vivace Therapeutics, Inc., a biotechnology company focused on developing small molecule cancer therapies that target the Hippo pathway, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA)

Made Scientific, a leading clinical and commercial-enabling cell therapy contract development and manufacturing organization (CDMO), and Streamline Bio, a next-generation autonomous robotics company solving critical challenges

AbbVie today announced the start of construction of its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, Illinois.